Argent BioPharma Ltd
Argent BioPharma Licences CannEpil Globally in US$5.5m Debt-Clearing Transaction
Argent BioPharma inks global CannEpil license with Splash Beverage, US$5.5m upfront debt-clearing, 15% royalty; boosts US growth and potential listing.
Argent BioPharma Signs $15m Deal to Acquire Key Clinical and IP Assets from AusCann
Argent BioPharma (ASX: RGT) has signed a binding term sheet to acquire the key assets of AusCann Group Holdings, a deal designed to expand its clinical pipeline, intellectual property (IP) portfolio, and European presence. The US$15 million scrip-based transaction will see AusCann receive 25 million Argent shares at US$0.60 each, with completion expected in the […]
Argent BioPharma to Supply Cannabinoid Treatment for Drug-Resistant Epilepsy in Slovenia
Argent BioPharma (ASX: RGT) has commenced the supply of a cannabinoid-based active pharmaceutical ingredient (API) to treat refractory (or drug-resistant) epilepsy patients at Slovenia’s largest hospital. The API will be transitioned to routine use at the paediatric clinic within University Medical Centre Ljubljana (UMCL) following a successful pilot program, enabling neurologists to dispense recommended, protocol-aligned […]
Argent BioPharma gains approval for prescription sales of CannEpil epilepsy treatment in Germany
Argent BioPharma’s (ASX: RGT) flagship CannEpil cannabinoid-based therapy for the treatment of refractory (or drug-resistant) epilepsy has been approved for prescription in Germany under a special access scheme. The approval means that doctors can now prescribe the drug to eligible patients, who may also qualify for health insurance coverage depending on the doctor’s recommendation and […]